eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
1/2022
vol. 47
 
Share:
Share:
more
 
 
abstract:
Review paper

Novel therapies for diabetic retinopathy

Magdalena Kupis
1
,
Katarzyna Samelska
1
,
Jacek Szaflik
1
,
Piotr Skopiński
2

1.
Department of Ophthalmology, Medical University of Warsaw, Warsaw, Poland
2.
Department of Histology and Embryology, Medical University of Warsaw, Warsaw, Poland
Cent Eur J Immunol 2022; 47 (1): 102-108
Online publish date: 2022/01/28
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Diabetes mellitus (DM) is a metabolic disease characterized by high blood glucose levels as well as microvascular and macrovascular changes. According to the latest statistics the growth of DM incidence is very fast. Diabetic retinopathy (DR) – one of the common DM complications – is the leading cause of blindness among professionally active people. Traditional treatment of DR including drugs controlling hyperglycemia, laser therapy, vitrectomy, and intravitreal injections of anti-VEGF is effectively administered with the effect of neovascularization and macular edema prevention. However, new potential DR therapies – focusing on a longer therapeutic effect and potentially fewer side effects – are being widely investigated. Gene therapy – targeting retinal vasculopathy or targeting retinal protection, mesenchymal stem cell injections, SGLT2 inhibitors, and islet cell transplantation have been proved to stop DR progression. The majority of the new treatment research was performed on an animal model and did not reach the final study stage. A further future human model and randomized studies with optimized delivery vectors will hopefully confirm positive outcomes of the new DR therapies.
keywords:

diabetic retinopathy, gene therapy, mesenchymal stem cells, SGLT2 inhibitors, islet cell transplantation

Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.